Royalty Pharma plc (NASDAQ:RPRX) Receives $42.50 Consensus PT from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been given a consensus rating of “Buy” by the five ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $42.50.

Several equities analysts recently issued reports on the stock. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Monday, May 12th. Finally, Morgan Stanley initiated coverage on Royalty Pharma in a report on Friday. They issued an “overweight” rating and a $51.00 target price on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in shares of Royalty Pharma by 42.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company’s stock valued at $432,862,000 after acquiring an additional 5,069,127 shares during the period. Swedbank AB raised its holdings in Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after purchasing an additional 1,136,800 shares during the last quarter. Geode Capital Management LLC lifted its position in Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company’s stock valued at $186,846,000 after purchasing an additional 46,765 shares during the period. Norges Bank acquired a new position in Royalty Pharma during the 4th quarter valued at about $124,498,000. Finally, Two Sigma Advisers LP boosted its stake in shares of Royalty Pharma by 21.1% in the 4th quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company’s stock valued at $93,703,000 after purchasing an additional 640,000 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Up 0.7%

Shares of RPRX opened at $34.25 on Friday. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $34.32. The firm has a market capitalization of $19.74 billion, a P/E ratio of 23.62, a P/E/G ratio of 2.31 and a beta of 0.49. The company has a 50-day simple moving average of $32.42 and a 200-day simple moving average of $30.06. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million for the quarter, compared to analysts’ expectations of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities research analysts expect that Royalty Pharma will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Friday, May 16th. Royalty Pharma’s dividend payout ratio is currently 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.